• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents - Global Forecasts to 2019 - Product Image

Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents - Global Forecasts to 2019

  • ID: 2334472
  • January 2015
  • Region: Global
  • 187 Pages
  • Markets and Markets
The market is expected to reach $797 million by 2019, at CAGR of 6.0% from 2014 to 2019.

FEATURED COMPANIES

  • Aspect Imaging
  • Biospace Lab S.A.
  • Bruker Corporation
  • Li-Cor Biosciences
  • Mediso Ltd.
  • Milabs B.V.
  • MORE

Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019

The global preclinical imaging market is estimated to grow at a CAGR of 6.0% from 2014 to 2019. Although mature markets (such as the U.S., Germany, France, and the U.K.) hold larger shares in the preclinical imaging market in 2014, the Asia-Pacific region is poised to grow at the highest CAGR of 8.2% in the next five years. Factors such as increased outsourcing of preclinical research activities to Asia-based CROs by big pharmaceutical and biotechnological companies, owing to low cost of research in these nations; and increased government funding for drug discovery and development activities in economically emerging counties are propelling the growth of the preclinical imaging market in Asia-Pacific region.

The growth of the global preclinical imaging market is driven by factors such as development of technologically advanced hybrid preclinical imaging systems such as PET/CT, PET/MRI, and PET/SPECT/CT; growing acceptance READ MORE >

Note: Product cover images may vary from those shown
The market is expected to reach $797 million by 2019, at CAGR of 6.0% from 2014 to 2019.

FEATURED COMPANIES

  • Aspect Imaging
  • Biospace Lab S.A.
  • Bruker Corporation
  • Li-Cor Biosciences
  • Mediso Ltd.
  • Milabs B.V.
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Pre-Clinical Imaging Market Definition
1.3 Pre-Clinical Imaging Market Scope
1.3.1 Pre-Clinical Imaging Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Breakdown of Primaries
2.1.2.2 Key Data From Primary Sources
2.1.2.3 Key Industry Insights
2.2 Pre-Clinical Imaging Market Size Estimation
2.2.1.1 Bottom-Up Approach
2.2.1.2 Top-Down Approach
2.3 Breakdown and Data Triangulation
2.4 Research Assumptions

3 Executive Summary
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights
4.1 Attractive Market Opportunities in the Pre-Clinical Imaging Market
4.2 Pre-Clinical Imaging Reagents Markets, By Region (2014)
4.3 Pre-Clinical Imaging Systems, By Region (2014)
4.4 Pre-Clinical Imaging Systems Market, By Modality, (2014–2019)

5 Market Overview
5.1 Introduction
5.2 Pre-Clinical Imaging Market Segmentation
5.2.1 Pre-Clinical Imaging Market Segmentation, By Modality
5.2.2 Pre-Clinical Imaging Market Segmentation, By Reagent
5.3 Pre-Clinical Imaging Market Dynamics
5.3.1 Drivers
5.3.1.1 Advancements in Molecular Imaging Technologies
5.3.1.2 Growing Acceptance of Pre-Clinical Imaging as A Legitimate Drug Development Tool
5.3.1.3 Increasing Demand for Multi-Modality Imaging Technologies in Pre-Clinical Research
5.3.1.4 Increasing Number of Pre-Clinical Research Activities
5.3.2 Restraints
5.3.2.1 High Implementation Costs of Imaging Systems
5.3.2.2 Reduced Nih Funding for Life Science Research Activities
5.3.2.3 High Cost and Data Requirements for Developing New Imaging Technologies
5.3.3 Opportunities
5.3.3.1 Emerging Markets Offer Lucrative Growth Opportunities for Pre-Clinical Imaging Market Players
5.3.3.2 Major Companies Exiting From the Pre-Clinical Imaging Market is Opening New Growth Avenues for Existing Market Players
5.3.3.3 Integration of Preclinical MRI Systems With Other Imaging Modalities
5.3.3.4 Development of Low-Cost Imaging Devices With High Resolution and Sensitivity
5.3.4 Challenges
5.3.4.1 Technological Limitations of Standalone Pre-Clinical Imaging Modalities
5.3.4.2 Challenges Associated With the Application of Radioisotopes Negatively Affects the Demand of Micro-PET Systems

6 Industry Insights
6.1 Introduction
6.2 Value Chain Analysis
6.3 Supply Chain Analysis
6.3.1 Key Stakeholders
6.3.2 Key Influencers
6.4 Industry Trends
6.4.1 Rising Focus of Market Players Towards the Development of Hybrid Pre-Clinical Imaging Systems
6.4.2 Increasing Government Funding for Pharmaceutical Research and Development in Emerging Nations
6.5 Porter’s Five Forces Analysis
6.5.1 Threat From New Entrants
6.5.2 Threat From Substitutes
6.5.3 Bargaining Power of Suppliers
6.5.4 Bargaining Power of Buyers
6.5.5 Intensity of Competitive Rivalry

7 Global Pre-Clinical Imaging Market, By Modality
7.2 Introduction
7.3 Optical Imaging Systems
7.3.1 Bioluminescence/Fluorescence Imaging Systems
7.3.2 Standalone Fluorescence Imaging Systems
7.3.3 Optical + X-Ray/Optical + CT
7.4 Pre-Clinical Nuclear Imaging Systems
7.4.1 Micro-PET Systems
7.4.1.1 Standalone PET Systems
7.4.1.2 PET/CT Systems
7.4.1.3 PET/MRI Systems
7.4.2 Micro-SPECT Systems
7.4.2.1 Standalone SPECT Systems
7.4.2.2 SPECT/CT Systems
7.4.2.3 SPECT/MRI Systems
7.4.3 Trimodality (SPECT/PET/CT) Systems
7.5 Micro-MRI
7.6 Micro-Ultrasound
7.7 Micro-CT
7.8 Pre-Clinical Photoacoustic Imaging Systems
7.9 Pre-Clinical Magnetic Particle Imaging (MPI) Systems

8 Global Pre-Clinical Imaging Market, By Reagents
8.1 Introduction
8.2 Pre-Clinical Optical Imaging Reagents
8.2.1 Bioluminescent Imaging Reagents
8.2.1.1 Luciferins
8.2.1.2 Proluciferins
8.2.1.3 Coelenterazine
8.2.1.4 Others
8.2.2 Fluorescent Imaging Reagents
8.2.2.1 Green Fluorescent Proteins
8.2.2.2 Red Fluorescent Proteins
8.2.2.3 Infrared Dyes
8.2.2.4 Others (Natural Fluorescence Molecules Such as Collagen and Elastin)
8.3 Pre-Clinical Nuclear Imaging Reagents
8.3.1 Pre-Clinical PET Tracers
8.3.1.1 Fluorine-18-Based Preclinical PET Tracers
8.3.1.2 Carbon-11-Based Preclinical PET Tracers
8.3.1.3 Copper-64-Based Preclinical PET Tracers
8.3.1.4 Others
8.3.2 Pre-Clinical SPECT Probes
8.3.2.1 Technetium-99m-Based Preclinical SPECT Probes
8.3.2.2 Iodine-131-Based Preclinical SPECT Probes
8.3.2.3 Gallium-67-Based Preclinical SPECT Probes
8.3.2.4 Thallium-201-Based Preclinical SPECT Probes
8.3.2.5 Others
8.4 Pre-Clinical MRI Contrast Agents
8.4.1 Gadolinium-Based Pre-Clinical MRI Contrast Agents
8.4.2 Iron-Based Pre-Clinical MRI Contrast Agents
8.4.3 Manganese-Based Pre-Clinical MRI Contrast Agents
8.5 Pre-Clinical Ultrasound Contrast Agents
8.6 Pre-Clinical CT Contrast Agents
8.6.1 Iodine-Based Pre-Clinical CT Contrast Agents
8.6.2 Barium-Based Pre-Clinical CT Contrast Agents
8.6.3 Gold Nanoparticles
8.6.4 Gastrografin-Based Pre-Clinical CT Contrast Agents

9 Geographic Analysis
9.1 Introduction
9.2 North America
9.3 Europe
9.4 Asia-Pacific
9.5 Rest of the World (RoW)

10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis: Pre-Clinical Imaging Market, By Key Player, 2013
10.3 Competitive Situation and Trends
10.3.1 New Product Launches and Product Developments
10.3.2 Agreements, Partnerships, and Collaborations
10.3.3 Geographical Expansions
10.3.4 Mergers and Acquisitions
10.3.5 Other Developments

11 Company Profiles
11.1 Perkinelmer, Inc.
11.1.1 Business Overview
11.1.2 Product Portfolio
11.1.3 Key Strategy
11.1.4 Key Developments (2012-2014)
11.1.5 SWOT Analysis
11.2 Bruker Corporation
11.2.1 Business Overview
11.2.2 Product Portfolio
11.2.3 Key Strategy
11.2.4 Key Developments (2012–2014)
11.2.5 SWOT Analysis
11.3 Fujifilm Visualsonics, Inc.
11.3.1 Business Overview
11.3.2 Product Portfolio
11.3.3 Key Strategy
11.3.4 Key Developments (2012–2014)
11.3.5 SWOT Analysis
11.4 Mediso Ltd.
11.4.1 Business Overview
11.4.2 Product Portfolio
11.4.3 Key Strategy
11.4.4 Key Developments (2012–2014)
11.4.5 SWOT Analysis
11.5 Trifoil Imaging
11.5.1 Business Overview
11.5.2 Product Portfolio
11.5.3 Key Strategy
11.5.4 Key Developments (2012–2014)
11.6 Mr Solutions Ltd.
11.6.1 Business Overview
11.6.2 Product Portfolio
11.6.3 Key Strategy
11.6.4 Key Developments (2012-2014)
11.7 Aspect Imaging
11.7.1 Business Overview
11.7.2 Product Portfolio
11.7.3 Key Strategy
11.7.4 Key Developments (2012–2014)
11.8 Biospace Lab S.A.
11.8.1 Business Overview
11.8.2 Product Portfolio
11.8.3 Key Strategy
11.8.4 Key Developments (2012–2014)
11.9 Li-Cor Biosciences
11.9.1 Business Overview
11.9.2 Product Portfolio
11.9.3 Key Strategy
11.9.4 Key Developments (2012-2014)
11.1 Milabs B.V.
11.10.1 Business Overview
11.10.2 Product Portfolio
11.10.3 Key Strategy
11.10.4 Key Developments (2012–2014)

12 Appendix
12.1 Insights of Industry Experts
12.2 Discussion Guide*
12.3 Company Developments (2012–2014)
12.3.1 Aspect Imaging
12.3.2 Bruker Corporation
12.3.3 Li-Cor Biosciences
12.3.4 Mediso Ltd.
12.3.5 Milabs B.V.
12.3.6 Perkinelmer, Inc.
12.4 Introducing RT: Real-Time Market Intelligence
12.5 Available Customizations
12.6 Related Reports

List of Tables (84 Tables)

Table 1 Pre-Clinical Imaging Systems Market Size, By Modality, 2012–2019 ($Million)
Table 2 Systems Market Size, By Region, 2012–2019 ($Million)
Table 3 Global Optical Imaging Systems Market Size, By Type, 2012–2019 ($Million)
Table 4 Optical Imaging Systems Market Size, By Region, 2012–2019 ($Million)
Table 5 Bioluminescence/Fluorescence Imaging Systems Market Size, By Region, 2012–2014 ($Million)
Table 6 Standalone Fluorescence Imaging Systems Market Size, By Region, 2012–2014 ($Million)
Table 7 Optical + X-Ray/Optical + CT Imaging Systems Market Size, By Region, 2012–2014 ($Million)
Table 8 Global Pre-Clinical Nuclear Imaging Systems Market Size, By Type, 2012–2019 ($Million)
Table 9 Pre-Clinical Nuclear Imaging Systems Market Size, By Region, 2012–2019 ($Million)
Table 10 Global Micro-PET Systems Market Size, By Type, 2012–2019 ($Million)
Table 11 Micro-PET Systems Market Size, By Region, 2012–2019 ($Million)
Table 12 Standalone PET Systems Market Size, By Region, 2012–2019 ($Million)
Table 13 PET/CT Systems Market Size, By Region, 2012–2019 ($Million)
Table 14 PET/MRI Systems Market Size, By Region, 2012–2019 ($Million)
Table 15 Global Micro-SPECT Systems Market Size, By Type, 2012–2019 ($Million)
Table 16 Micro-SPECT Systems Market Size, By Region, 2012–2019 ($Million)
Table 17 Standalone SPECT Systems Market Size, By Region, 2012–2019 ($Million)
Table 18 SPECT/CT Systems Market Size, By Region, 2012–2019 ($Million)
Table 19 Micro-MRI Systems Market Size, By Region, 2012–2019 ($Million)
Table 20 Micro-Ultrasound Systems Market Size, By Region, 2012–2019 ($Million)
Table 21 Micro-CT Systems Market Size, By Region, 2012–2019 ($Million)
Table 22 Pre-Clinical Photoacoustic Imaging Systems Market Size, By Region, 2012–2019 ($Million)
Table 23 Global Pre-Clinical Imaging Reagents Market Size, By Type, 2012–2019 ($Million)
Table 24 Reagents Market Size, By Region, 2012–2019 ($Million)
Table 25 Global Pre-Clinical Optical Imaging Reagents Market Size, By Type, 2012–2019 ($Million)
Table 26 Pre-Clinical Optical Imaging Reagents Market Size, By Region, 2012–2019 ($Million)
Table 27 Global Pre-Clinical Bioluminescent Imaging Reagents Market Size, By Type, 2012–2019 ($Million)
Table 28 Pre-Clinical Bioluminescent Imaging Reagents Market Size, By Region, 2012–2019 ($Million)
Table 29 Pre-Clinical Luciferins Market Size, By Region, 2012–2019 ($Million)
Table 30 Pre-Clinical Proluciferins Market Size, By Region, 2012–2019 ($Million)
Table 31 Pre-Clinical Coelenterazine Market Size, By Region, 2012–2019 ($Million)
Table 32 Other Pre-Clinical Bioluminescent Imaging Reagents Market Size, By Region, 2012–2019 ($Million)
Table 33 Global Pre-Clinical Fluorescent Imaging Reagents Market Size, By Type, 2012–2019 ($Million)
Table 34 Pre-Clinical Fluorescent Imaging Reagents Market Size, By Region, 2012–2019 ($Million)
Table 35 Pre-Clinical Green Fluorescent Proteins Market Size, By Region, 2012–2019 ($Million)
Table 36 Pre-Clinical Red Fluorescent Proteins Market Size, By Region, 2012–2019 ($Million)
Table 37 Pre-Clinical Infrared Dyes Market Size, By Region, 2012–2019 ($Million)
Table 38 Other Pre-Clinical Fluorescent Imaging Reagents Market Size, By Region, 2012–2019 ($Million)
Table 39 Global Pre-Clinical Nuclear Imaging Reagents Market Size, By Type, 2012–2019 ($Million)
Table 40 Pre-Clinical Nuclear Imaging Reagents Market Size, By Region, 2012–2019 ($Million)
Table 41 Global Pre-Clinical PET Tracers Market Size, By Type, 2012–2019 ($Million)
Table 42 Pre-Clinical PET Tracers Market Size, By Region, 2012–2019 ($Million)
Table 43 Fluorine-18-Based Pre-Clinical PET Tracers Market Size, By Region, 2012–2019 ($Million)
Table 44 Carbon-11-Based Pre-Clinical PET Tracers Market Size, By Region, 2012–2019 ($Million)
Table 45 Copper-64-Based Pre-Clinical PET Tracers Market Size, By Region, 2012–2019 ($Million)
Table 46 Other Pre-Clinical PET Tracers Market Size, By Region, 2012–2019 ($Million)
Table 47 Global Pre-Clinical SPECT Probes Market Size, By Type, 2012–2019 ($Million)
Table 48 Pre-Clinical SPECT Probes Market Size, By Region, 2012–2019 ($Million)
Table 49 Technetium-99m-Based Pre-Clinical SPECT Probes Market Size, By Region, 2012–2019 ($Million)
Table 50 Iodine-131-Based Pre-Clinical SPECT Probes Market Size, By Region, 2012–2019 ($Million)
Table 51 Gallium-67-Based Pre-Clinical SPECT Probes Market Size, By Region, 2012–2019 ($Million)
Table 52 Thallium-201-Based Pre-Clinical SPECT Probes Market Size, By Region, 2012–2019 ($Million)
Table 53 Other Pre-Clinical SPECT Probes Market Size, By Region, 2012–2019 ($Million)
Table 54 Global Pre-Clinical MRI Contrast Agents Market Size, By Type, 2012–2019 ($Million)
Table 55 Pre-Clinical MRI Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 56 Gadolinium-Based Pre-Clinical MRI Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 57 Iron-Based Pre-Clinical MRI Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 58 Manganese-Based Pre-Clinical MRI Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 59 Pre-Clinical Ultrasound Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 60 Global Pre-Clinical CT Contrast Agents Market Size, By Type, 2012–2019 ($Million)
Table 61 Pre-Clinical CT Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 62 Iodine-Based Pre-Clinical CT Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 63 Barium-Based Pre-Clinical CT Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 64 Gold Nanoparticles Pre-Clinical CT Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 65 Gastrografin-Based Pre-Clinical CT Contrast Agents Market Size, By Region, 2012–2019 ($Million)
Table 66 Global Systems and Reagents Market Size, By Region, 2012-2019 ($Million)
Table 67 North America: Pre-Clinical Imaging Market, By Product, 2012-2019 ($Million)
Table 68 North America: Systems Market, By Modality, 2012-2019 ($Million)
Table 69 U.S.: Systems Market, By Modality, 2012-2019 ($Million)
Table 70 North America: Reagents Market, By Type, 2012-2019 ($Million)
Table 71 Europe: Pre-Clinical Imaging Market, By Product, 2012-2019 ($Million)
Table 72 Europe: Systems Market, By Modality, 2012-2019 ($Million)
Table 73 Europe: Reagents Market, By Type, 2012-2019 ($Million)
Table 74 Asia-Pacific: Pre-Clinical Imaging Market, By Product, 2012-2019 ($Million)
Table 75 Asia-Pacific: Systems Market, By Modality, 2012-2019 ($Million)
Table 76 Asia-Pacific: Reagents Market, By Type, 2012-2019 ($Million)
Table 77 RoW: Pre-Clinical Imaging Market, By Product, 2012-2019 ($Million)
Table 78 RoW: Systems Market, By Modality, 2012-2019 ($Million)
Table 79 RoW: Reagents Market, By Reagents, 2012-2019 ($Million)
Table 80 Top 5 New Product Launches and Product Developments, 2012–2014
Table 81 Top 5 Agreements, Partnerships, and Collaborations, 2012–2014
Table 82 Top 5 Geographical Expansions, 2012–2014
Table 83 Mergers and Acquisitions, 2012–2014
Table 84 Top 5 Other Developments, 2012–2014

List of Figures (65 Figures)

Figure 1 Pre-Clinical Imaging Market Research Methodology
Figure 2 Break Down of Supply Side Primary Interviews: By Company Type, Designation, and Region
Figure 3 Pre-Clinical Imaging Systems Market: Bottom Up Approach
Figure 4 Pre-Clinical Imaging Systems Market: Top-Down Approach
Figure 5 Pre-Clinical Imaging Reagents Market: Top-Down Approach
Figure 6 Pre-Clinical Imaging Market: Data Triangulation
Figure 7 Global Systems Market, 2014 ($Million)
Figure 8 Global Systems Market, 2014 vs. 2019
Figure 9 Global Reagents Market, 2014 vs. 2019
Figure 10 Global Pre-Clinical Imaging Market, By Region, 2014 ($Million)
Figure 11 Emerging Countries Offering High Growth Opportunities to Players in the Pre-Clinical Imaging Market
Figure 12 North America Commands the Largest Share of the Global Reagents Market
Figure 13 Optical, Nuclear, MRI, & Ultrasound Imaging Systems Command the Largest Share of the Global Systems Market
Figure 14 Over 80% of the Global Pre-Clinical Imaging Systems Market Will Be Dominated By Optical, Nuclear, & MRI Systems in 2019
Figure 15 Pre-Clinical Imaging Market Segmentation
Figure 16 Pre-Clinical Imaging Market Segmentation, By Modality
Figure 17 Pre-Clinical Imaging Reagents Market Segmentation, By Reagent
Figure 18 Pre-Clinical Imaging Market Drivers, Restraints, Opportunities, & Challenges
Figure 19 Advancements in Molecular Imaging Technologies Boosting the Adoption of These Systems in Pre-Clinical Research Studies
Figure 20 High Cost of Imaging Systems and Reduced Nih Funding Are Restricting the Growth of Pre-Clinical Imaging Market
Figure 21 Emerging Economies Offering High Growth Potential for Pre-Clinical Imaging Market
Figure 22 Technological Limitations of Individual Imaging Modalities is A Key Growth Challenge for Standalone Pre-Clinical Imaging Device Providers
Figure 23 Value Chain of Systems Market
Figure 24 Pre-Clinical Imaging Market Players Prefer Both Direct & Indirect Distribution Strategies
Figure 25 Porter’s Five Forces Analysis, 2014
Figure 26 Pre-Clinical Imaging Systems Market, By Modality, 2014 vs. 2019 ($Million): Nuclear Imaging Systems Market to Grow at the Fastest Rate
Figure 27 The Bioluminescence/Fluorescence Imaging Systems Segment Holds A Major Share of the Pre-Clinical Optical Imaging Systems Market (2014)
Figure 28 The Asia-Pacific Pre-Clinical Optical Imaging Systems Market is Expected to Grow at A High Rate From 2014 to 2019
Figure 29 The Asia-Pacific Pre-Clinical Bioluminescence/Fluorescence Imaging Systems Market is Expected to Grow at A Double Digit Rate During the Forecast Period
Figure 30 The Standalone Fluorescence Imaging Systems Market is Expected to Witness Sluggish Growth in All Geographic Regions
Figure 31 Demand for Optical + X-Ray/Optical + CT Imaging Systems is Expected to Grow Rapidly in the Asia-Pacific Region
Figure 32 The Micro-PET Systems Segment Holds the Largest Share of the Pre-Clinical Nuclear Imaging Systems Market in 2014
Figure 33 North America Covers the Largest Share of the Pre-Clinical Nuclear Imaging Systems Market in 2014
Figure 34 PET/MRI Systems Market is Expected to Grow at A Double-Digit Rate During the Forecast Period
Figure 35 Asia-Pacific is Expected to Outpace the European Micro-PET Systems Market By 2019
Figure 36 North America Will Continue to Dominate the Micro-SPECT Systems Market in the Next Five Years
Figure 37 The Asia-Pacific Micro-MRI Systems Market is Expected to Equal the Market Size of the North American Market By 2019
Figure 38 North America Will Continue to Dominate the Global Micro-Ultrasound Systems Market By 2019
Figure 39 North America Holds the Largest Share of the Global Micro-CT Systems Market in 2014
Figure 40 North America is Expected to Be the Second-Fastest-Growing Market for Pre-Clinical Photoacoustic Imaging Systems After Asia-Pacific During The Forecast Period
Figure 41 Global Reagents Market, 2014 vs. 2019 ($Million): MRI Contrast Agents Market to Grow at the Fastest Rate
Figure 42 Bioluminescent Imaging Reagents Segment Will Continue to Dominate the Pre-Clinical Optical Imaging Reagents Market in the Forecast Period
Figure 43 Asia-Pacific Pre-Clinical Optical Imaging Reagents Market is Expected to Grow at the Highest CAGR in the Next Five Years
Figure 44 Luciferins to Command the Largest Share of Bioluminescent Imaging Reagents Market in 2014
Figure 45 Asia-Pacific Region is Estimated to Witness the Highest Growth Rate in the Bioluminescent Imaging Reagents Market
Figure 46 Infrared Dyes Account for the Largest Share of Pre-Clinical Fluorescent Imaging Reagents Market in 2014
Figure 47 Asia-Pacific and ROW Regions Will Drive the Growth of Pre-Clinical Fluorescent Imaging Reagents Market During the Forecast Period
Figure 48 PET Tracers Will Continue to Dominate the Pre-Clinical Nuclear Imaging Reagents Market in the Next Five Years
Figure 49 North America Accounts for the Largest Share of the Global Pre-Clinical Nuclear Imaging Reagents Market in 2014
Figure 50 Fluorine-18-Based PET Tracers Command the Lion’s Share of Pre-Clinical PET Tracers Market in 2014
Figure 51 Technetium-99m-Based SPECT Probes Command the Lion’s Share of Pre-Clinical SPECT Probes Market in 2014
Figure 52 Gadolinium-Based MRI Contrast Agents Command the Largest Share of Pre-Clinical MRI Contrast Agents Market in 2014
Figure 53 Asia-Pacifica MRI Contrast Agents Market is Estimated to Grow at the Highest Rate During the Forecast Period
Figure 54 North America Accounts for the Major Share of the Pre-Clinical Ultrasound Contrast Agents Market in 2014
Figure 55 Iodine-Based Contrast Agents Hold the Largest Share of Pre-Clinical CT Contrast Agents Market in 2014
Figure 56 Pre-Clinical Imaging Market , By Region, 2014 vs. 2019 ($Million): Asia-Pacific to Grow at the Highest Rate During the Forecast Period
Figure 57 North American Pre-Clinical Imaging Market Snapshot (2014-2019): Growth is Driven By High Adoption of Innovative Technologies
Figure 58 European Pre-Clinical Imaging Market Snapshot (2014-2019): Growth is Driven By Increased Government Funding for Developing European Research Sector
Figure 59 Asia-Pacific Pre-Clinical Imaging Market Snapshot (2014-2019): Growth is Driven By Rising Government Investment in Pharmaceutical R&D
Figure 60 Leading Pre-Clinical Imaging Market Players Adopted New Product Launches as the Key Growth Strategy Over the Last Three Years (2012–2014)
Figure 61 Global Pre-Clinical Imaging Market Share, By Key Player, 2013
Figure 62 Battle for Pre-Clinical Imaging Market Share: New Product Launches is the Key Strategy
Figure 63 Perkinelmer, Inc.: Company Snapshot
Figure 64 Bruker Corporation: Company Snapshot
Figure 65 Fujifilm Holdings Corporation.: Company Snapshot

Note: Product cover images may vary from those shown
The market is expected to reach $797 million by 2019, at CAGR of 6.0% from 2014 to 2019.

FEATURED COMPANIES

  • Aspect Imaging
  • Biospace Lab S.A.
  • Bruker Corporation
  • Li-Cor Biosciences
  • Mediso Ltd.
  • Milabs B.V.
  • MORE

On the basis of products, the global pre-clinical imaging market is segmented into two broad categories, namely, systems and reagents. The systems market is divided into seven imaging modalities, namely, optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic, and magnetic particle imaging systems. The pre-clinical optical imaging systems market includes bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems, optical + X-ray/optical + CT imaging systems.

The pre-clinical nuclear imaging systems market consists of micro-PET systems (standalone PET, PET/CT, and PET/MRI), micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI), and trimodality (PET/SPECT/CT) imaging systems. The optical imaging systems segment is estimated to account for the largest share of the global pre-clinical imaging systems market in 2014. The nuclear imaging systems segment is expected to grow at the highest CAGR in the next five years, owing to development of technologically hybrid nuclear imaging systems and their rising adoption in pre-clinical research studies.

The reagents market has also been classified into five categories, namely, optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. The optical imaging reagents market is further subsegmented as bioluminescent and fluorescent imaging reagents. Likewise, the nuclear imaging reagents market is divided as pre-clinical PET tracers and SPECT probes.

This report studies the global pre-clinical imaging market over the forecast period of 2014 to 2019. The market is expected to reach $797 million by 2019, at CAGR of 6.0% from 2014 to 2019.

A number of factors such as technological developments in molecular imaging technologies such as PET and MRI, rising acceptance of preclinical imaging as a legitimate drug development tool, and increasing number of pre-clinical research activities are propelling the growth of the global pre-clinical imaging market. However, high cost of imaging systems, reduced NIH (National Institutes of Health) funding for life science research activities, and high cost and data requirements for bringing new imaging technology are some of the major factors restraining the growth of the market. In addition to this, challenges associated with the application of radioisotopes, such as short half- life of PET radioisotopes and high cost involved in the generation of these isotopes, limits the demand for micro-PET systems, especially in developing countries where budget scarcity is a major issue with life science researchers.

On the basis of geography, pre-clinical imaging market is classified into four regions, namely, North America, Europe, Asia-Pacific, and Rest of the World. In 2014, the global pre-clinical imaging market is estimated to be dominated by North America. A number of factors such as the high volume of pre-clinical research studies, technological advancements, and well-established infrastructure to conduct pre-clinical research are driving the growth of the market in the North American region. The Asia-Pacific market is expected to grow at the highest CAGR from 2014 to 2019. This is primarily due to the factors such as rising number of CROs offering pre-clinical research studies and increasing outsourcing of preclinical research by global pharma companies to developing Asian countries. Furthermore, rising government investment to develop pharmaceutical R&D in emerging nations is also intensifying the number of pre-clinical research studies in this region.

New product launches is the key growth strategy adopted by the major players to develop their position in the global pre-clinical imaging market. Moreover, strategies such as partnerships, agreements, collaborations, expansions, and acquisitions were also adopted by a significant number of market players to strengthen their product portfolio and expand their geographic presence in this market.

Aspect Imaging (Israel), Biospace Lab S.A. (France), Bruker Corporation (U.S.), LI-COR Biosciences (U.S.), Mediso Ltd. (Hungary), MILabs B.V. (Netherlands), MR Solutions Ltd (U.K.), PerkinElmer, Inc. (U.S.), TriFoil Imaging (U.S.), and FUJIFILM VisualSonics, Inc. (Canada) are the key players operating in the global pre-clinical imaging market .

Note: Product cover images may vary from those shown
The market is expected to reach $797 million by 2019, at CAGR of 6.0% from 2014 to 2019.

- Aspect Imaging
- Biospace Lab S.A.
- Bruker Corporation
- Fujifilm Visualsonics, Inc.
- Li-Cor Biosciences
- Mediso Ltd.
- Milabs B.V.
- Mr Solutions Ltd.
- Perkinelmer, Inc.
- Trifoil Imaging

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

AGFA Healthcare N.V. Samsung Group Ltd. Varian Medical Systems, Inc. Siemens AG Bruker Corporation Medical Modeling, Inc.